Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia

Documenti analoghi

• Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents
  di: Isla M. Johnson, et al.
  Pubblicazione: (2024)
• The heart of VIALE‐A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia
  di: Shyam A. Patel
  Pubblicazione: (2024)
• Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study
  di: Elisabetta Petracci, et al.
  Pubblicazione: (2025)
• Venetoclax resistance in acute myeloid leukaemia—Clinical and biological insights
  di: Boaz Nachmias, et al.
  Pubblicazione: (2024)
• Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis
  di: Barbora Weinbergerová, et al.
  Pubblicazione: (2024)